Drug Trial Radar · NCT02308527
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Jul 2013
Primary completion
Aug 1, 2021
Study completion Feb 18, 2026
Sponsor
- Lead sponsor
- University of BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; Roche Pharma AG; Imagine for Margo; EUSA Pharma, Inc.
- First posted
- Dec 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to Temozolomide increases the activity of chemotherapy.The primary objective of the study is the best response (Complete Response or Partial Response) while trial treatment, within 18 or 24 weeks depending on the arm of the trial the participant is randomised to. Secondary endpoints are assessing the side effects, the length of time before progression (Progression Free Survival) and overall survival (OS). This trial will address two important questions: * does targeting blood vessel development using bevacizumab, (a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour when used with existing chemotherapy, compared to the effect of the existing chemotherapy alone (temozolomide)? NOTE- This question has been completed. * does the addition of a second chemotherapy drug (irinotecan or topotecan) increase the effect on a tumour compared to the effect of one alone (temozolomide) NOTE - This question has been completed. * does the addition of dinutuximab beta added to a backbone chemotherapy (temozolomide or temozolomide + topotecan) increase the effect of backbone alone. Patients aged 1-21 years of age with relapsed or refractory high-risk neuroblastoma are randomised to one of two treatment arms: temozolomide-topotecan (TTo) or dinutuximab beta-temozolomide-topotecan (dBTTo). Temozolomide (T), irinotecan-temozolomide (IT), bevacizumab-T (BT), BIT (bevacizumab-IT), bevacizumab-temozolomide-topotecan (BTTo) and dinutuximab beta-temozolomide (dBT) are now closed to recruitment.
Conditions
- Neuroblastoma
Interventions
BevacizumabDrug
10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
TemozolomideDrug
200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
TemozolomideDrug
100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
IrinotecanDrug
50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
BevacizumabDrug
15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
TopotecanDrug
0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
TemozolomideDrug
150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Dinutuximab BetaDrug
10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
CyclophosphamideDrug
250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to.Time frame: Within 18 or 24 weeks depending on the arm of the trial the participant is randomised to.
- For the bevacizumab part 2 only; Progression-free survival (PFS)Time frame: Assessment will be after 30 days after treatment or end of trial
Locations
10 sites in 10 countries. Site status is shown where the registry gives one.
St Anna Children's Hospital and CCRI/Studies and Statistics
Vienna, Austria
University Hospital
Ghent, Belgium
University Hospital Rigshospitalet
Copenhagen, Denmark
Hopital des Enfants
Toulouse, France
Our Ladys Children's Hospital Dublin
Dublin, Ireland
Ospedale Pediatrico Bambino Gseu
Rome, Italy
Natasha van Eijkelenburg
Utrecht, Netherlands
Instituto de Investigacion Sanitaria
Valencia, Spain
Swiss Paediatric Oncology Group
Bern, Switzerland
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.